中文

九强生物 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-27
ItemAmountY/Y
Revenue¥0.33B+4.7%
Gross profit¥0.27B
Operating income¥0.12B
Net income¥0.11B+26.4%
Gross margin81.9%Net margin 31.5%
Revenue Q/Q-2.6%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.06B18.1%
R&D¥0.04B12.1%
SG&A¥0.10B30.0%
Tax & other¥0.02B5.5%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

凯发电气道氏技术正业科技金盾股份迦南科技中光防雷伊之密苏试试验南华仪器ST浩丰五洋自控力星股份

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies